Myozyme and central line infection 
Myozyme and central line infection Patient Reports February 10, 2010
Myozyme Side Effects Report #5935024-6
Myozyme side effect was reported by a Physician from ISRAEL on Oct 15, 2008. Male patient, child 2 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: cardiac hypertrophy, cardiomyopathy
, central line infection, cyanosis, deafness neurosensory, disease progression, electromyogram abnormal, hypotension, hypotonia. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with CORTICOSTEROIDS, PHENERGAN, HYDROCORTISONE. Patient was hospitalized and became disabled. Patient recovered.Myozyme Side Effects Report #6023234-1
Myozyme side effect was reported by a Physician from ISRAEL on Dec 11, 2008. Male patient, child 2 years of age, weighting 26.46 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: acute respiratory failure, cardiac hypertrophy, cardiomyopathy
, central line infection, cough, cyanosis, deafness neurosensory, disease progression, electromyogram abnormal. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with CORTICOSTEROIDS, PHENERGAN, HYDROCORTISONE. Patient was hospitalized and became disabled. Patient recovered.Myozyme Side Effects Report #6028578-5
Myozyme side effect was reported by a Physician from ISRAEL on Dec 22, 2008. Male patient, child 2 years of age, weighting 26.46 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: acute respiratory failure, central line infection, deafness neurosensory, disease progression, electromyogram abnormal, hypertrophic cardiomyopathy, hypotension, hypotonia, infusion related reaction. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with CORTICOSTEROIDS, PHENERGAN, HYDROCORTISONE, ASPIRIN. Patient was hospitalized and became disabled. Patient recovered.
Myozyme Side Effects Report #6032049-X
Myozyme side effect was reported by a Physician from ISRAEL on Dec 24, 2008. Male patient, child 2 years of age, weighting 26.46 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: acute respiratory failure, alanine aminotransferase increased, aspartate aminotransferase increased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, cardiac hypertrophy, central line infection, cyanosis, deafness neurosensory. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with CORTICOSTEROIDS, PHENERGAN, HYDROCORTISONE, ASPIRIN. Patient was hospitalized and became disabled. Patient recovered.
Myozyme Side Effects Report #6070365-6
Myozyme side effect was reported by a Physician from ISRAEL on Jan 21, 2009. Male patient, child 2 years of age, weighting 26.46 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: acute respiratory failure, alanine aminotransferase increased, aspartate aminotransferase increased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, central line infection, constipation
, deafness neurosensory, disease progression. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with CORTICOSTEROIDS, PHENERGAN, HYDROCORTISONE, ASPIRIN. Patient was hospitalized and became disabled. Patient recovered.Myozyme Side Effects Report #6078406-7
Myozyme side effect was reported by a Health Professional from UNITED STATES on Feb 06, 2009. Male patient, child 2 years of age, weighting 28.66 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: blood culture positive, central line infection, gastroenteritis viral, retching, salivary hypersecretion, staphylococcal infection
, tracheobronchitis. Myozyme dosage: 20 M G/KG, Q2W, INTRAVENOUS, 30 MG/KG, Q2W, INTRAVENOUS, 40 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with BENADRYL, ACETAMINOPHEN. Patient was hospitalized. Patient recovered.Myozyme Side Effects Report #6112213-1
Myozyme side effect was reported by a Health Professional from UNITED STATES on Feb 26, 2009. Male patient, child 2 years of age, weighting 28.66 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: central line infection, diarrhoea, gastroenteritis viral, nausea
, pyrexia, retching, salivary hypersecretion, staphylococcal infection , tracheobronchitis. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS; 30 MG/KG, Q2W, INTRAVENOUS; 40 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with BENADRYL, ACETAMINOPHEN. Patient was hospitalized. Patient recovered.Myozyme Side Effects Report #6138952-4
Myozyme side effect was reported by a Health Professional from UNITED STATES on Mar 20, 2009. Male patient, child 2 years of age, weighting 28.66 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: central line infection, diarrhoea, gastroenteritis viral, nausea
, retching, salivary hypersecretion, staphylococcal infection , tracheobronchitis. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS; 30 MG/KG, Q2W, INTRAVENOUS; 40 MG/KG, Q2W, INTRAVENOUS . During the same period patient was treated with BENADRYL, ACETAMINOPHEN. Patient was hospitalized. Patient recovered.Myozyme Side Effects Report #5209170-9
Myozyme side effect was reported by a Physician from UNITED STATES on Dec 28, 2006. Male patient, weighting 12.13 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: asthenia, blood creatine phosphokinase increased, blood culture positive, candidiasis, central line infection, condition aggravated, enterococcal infection, feeding disorder, hyporeflexia. Myozyme dosage: 20 MG/KG Q2WKS IV. During the same period patient was treated with BUDESONIDE, XOPENEX, LANSOPRAZOLE, DIGOXIN, PROPRANOLOL, AMIODARONE. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5218784-1
Myozyme side effect was reported by a Physician from UNITED STATES on Jan 09, 2007. Male patient, weighting 12.13 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: asthenia, blepharospasm, blood creatine phosphokinase increased, blood culture positive, candidiasis, cardiac disorder, central line infection, endotracheal intubation complication, enterococcal infection. Myozyme dosage: 20 MG/KG Q2WKS IV. During the same period patient was treated with BUDESONIDE, XOPENEX, LANSOPRAZOLE, DIGOXIN, PROPRANOLOL, AMIODARONE. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5233304-3
Myozyme side effect was reported by a Physician from UNITED STATES on Jan 26, 2007. Male patient, weighting 12.13 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: asthenia, blood creatine phosphokinase increased, blood immunoglobulin g increased, c-reactive protein increased, candidiasis, central line infection, echocardiogram abnormal, enterococcal infection, eyelid function disorder. Myozyme dosage: 20 MG/KG Q2WKS IV. During the same period patient was treated with BUDESONIDE, XOPENEX, LANSOPRAZOLE, DIGOXIN, PROPRANOLOL, AMIODARONE, BENADRYL. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5255199-4
Myozyme side effect was reported by a Physician from ITALY on Feb 14, 2007. Female patient, weighting 14.33 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: central line infection, cyanosis, hypotension, oxygen saturation decreased, viral infection
. Myozyme dosage: 20 MG/KG Q2WKS IV. Patient recovered.Myozyme Side Effects Report #5293817-5
Myozyme side effect was reported by a Physician from ITALY on Mar 22, 2007. Female patient, weighting 14.33 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: central line infection, cyanosis, hypotension, infusion related reaction, oxygen saturation decreased. Myozyme dosage: 20 MG/KG Q2WKS IV. Patient recovered.
Myozyme Side Effects Report #5294076-X
Myozyme side effect was reported by a Physician from UNITED STATES on Mar 23, 2007. Male patient, weighting 12.13 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: asthenia, blood creatine phosphokinase increased, blood culture positive, blood immunoglobulin g decreased, candidiasis, central line infection, developmental delay, enterococcal infection, eyelid disorder. Myozyme dosage: 20 MG/KG, Q2WKS; IV. During the same period patient was treated with BUDESONIDE, XOPENEX, LANSOPRAZOLE, DIGOXIN, PROPRANOLOL, AMIODARONE, BENADRYL. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5294077-1
Myozyme side effect was reported by a Health Professional from UNITED STATES on Mar 23, 2007. Male patient, weighting 11.68 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: bacteraemia, blepharospasm, blood culture positive, blood immunoglobulin g increased, body temperature decreased, bronchial hyperreactivity, central line infection, condition aggravated, device related infection. Myozyme dosage: unknown. During the same period patient was treated with BACTRIM. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5339706-9
Myozyme side effect was reported by a Physician from UNITED STATES on May 11, 2007. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: blood urine, bronchial hyperreactivity, candidiasis, central line infection, eosinophilia, haematuria, influenza, infusion related reaction, protein urine present. Myozyme dosage: 20 MG/KG Q2WKS IV. During the same period patient was treated with METHOTREXATE. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5361077-2
Myozyme side effect was reported by a Physician from UNITED STATES on May 30, 2007. Male patient, weighting 13.01 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: bronchial hyperreactivity, candidiasis, central line infection, eosinophilia, haematuria, proteinuria, respiratory tract infection, staphylococcal infection
, tachycardia. Myozyme dosage: 10 MG/KG Q2WKS IV. During the same period patient was treated with METHOTREXATE. Patient was hospitalized. Patient recovered.Myozyme Side Effects Report #5362838-6
Myozyme side effect was reported by a Physician from UNITED STATES on June 01, 2007. Male patient, weighting 15.38 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: bacterial sepsis, central line infection, coagulopathy, diaphragmatic disorder, disease progression, enterobacter infection, heart rate increased, hypercapnia, hypotension. Myozyme dosage: 30 MG/KG Q2WKS IV. During the same period patient was treated with METHOTREXATE, RITUXIMAB, IMMUNE GLOBULIN INTRAVENOUS. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5371492-9
Myozyme side effect was reported by a Physician from UNITED STATES on June 08, 2007. Male patient, weighting 13.01 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: albuminuria, bronchial hyperreactivity, candidiasis, central line infection, eosinophilia, haematuria, influenza, proteinuria, pyrexia. Myozyme dosage: 10 MG/KG Q2WKS IV. During the same period patient was treated with METHOTREXATE. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5384925-9
Myozyme side effect was reported by a Physician from UNITED STATES on June 25, 2007. Male patient, weighting 13.01 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, bronchial hyperreactivity, candidiasis, central line infection, eosinophilia, hypotension, influenza, renal failure acute. Myozyme dosage: 10 MG/KG Q2WKS IV. During the same period patient was treated with DIGOXIN, POTASSIUM CHLORIDE, CALCIUM GLUBIONATE, PROCRIT, BENADRYL, TYLENOL, FERROUS SULPHATE. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5394686-5
Myozyme side effect was reported by a Physician from UNITED STATES on July 09, 2007. Male patient, weighting 13.01 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, bronchial hyperreactivity, candidiasis, central line infection, enzyme inhibition, eosinophilia, hypotension, influenza serology positive. Myozyme dosage: 10 MG/KG QWKS IV. During the same period patient was treated with METHOTREXATE, CAPTOPRIL, FUROSEMIDE, DIGOXIN, POTASSIUM CHLORIDE, CALCIUM GLUBIONATE, PROCRIT. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5523090-1
Myozyme side effect was reported by a Physician from UNITED STATES on Nov 06, 2007. Male patient, weighting 15.38 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, bacteraemia, bacterial sepsis, blood calcium abnormal, bronchial hyperreactivity, catheter related infection, central line infection, coagulopathy, diaphragm muscle weakness. Myozyme dosage: 30 MG/KG Q2WKS IV. During the same period patient was treated with METHOTREXATE, RITUXIMAB, IMMUNE GLOBULIN INTRAVENOUS. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5566507-9
Myozyme side effect was reported by a Health Professional from UNITED STATES on Nov 30, 2007. Male patient, weighting 11.68 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: bacteria stool identified, bronchial hyperreactivity, central line infection, condition aggravated, enterobacter bacteraemia, eyelid function disorder, haemoglobin decreased, lobar pneumonia, nystagmus. Myozyme dosage: 20 MG/KG Q2WKS IV. During the same period patient was treated with BACTRIM, RITUXIMAB, METHOTREXATE, BENADRYL, TYLENOL. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5566508-0
Myozyme side effect was reported by a Physician from UNITED STATES on Nov 30, 2007. Male patient, weighting 12.13 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: asthenia, blood creatine phosphokinase increased, blood culture positive, candidiasis, cardiac disorder, catheter related infection, central line infection, clostridial infection, enterococcal infection. Myozyme dosage: 20 MG/KG Q2WKS IV. During the same period patient was treated with BUDESONIDE, XOPENEX, LANSOPRAZOLE, DIGOXIN, PROPRANOLOL, AMIODARONE. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5566517-1
Myozyme side effect was reported by a Physician from UNITED STATES on Nov 30, 2007. Male patient, weighting 15.38 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: areflexia, bronchial hyperreactivity, candidiasis, central line infection, cleft lip
, coagulopathy, condition aggravated, diaphragm muscle weakness, disease progression. Myozyme dosage: 30 MG/KG Q2WKS IV. During the same period patient was treated with METHOTREXATE, RITUXIMAB, IMMUNE GLOBULIN INTRAVENOUS. Patient was hospitalized. Patient recovered.Myozyme Side Effects Report #5706625-5
Myozyme side effect was reported by a Health Professional from UNITED STATES on Apr 02, 2008. Male patient, weighting 11.68 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: bacteraemia, bacteria stool identified, bronchial hyperreactivity, catheter related infection, central line infection, clostridial infection, enterobacter infection, eyelid disorder, lobar pneumonia. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with BACTRIM, RITUXIMAB, METHOTREXATE, BENADRYL, ACETAMINOPHEN. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5729660-X
Myozyme side effect was reported by a Physician from ISRAEL on Apr 21, 2008. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: cardiac hypertrophy, central line infection, cyanosis, deafness neurosensory, disease progression, dysstasia, electromyogram abnormal, hypotension. Myozyme dosage: unknown. During the same period patient was treated with CORTICOSTEROIDS, PHENERGAN, HYDROCORTISONE. Patient was hospitalized and became disabled. Patient recovered.
Myozyme Side Effects Report #5768470-4
Myozyme side effect was reported by a Physician from ISRAEL on June 03, 2008. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: cardiac hypertrophy, central line infection, cyanosis, deafness neurosensory, disease progression, electromyogram abnormal, hypotension, hypotonia. Myozyme dosage: unknown. During the same period patient was treated with CORTICOSTEROIDS, PHENERGAN, HYDROCORTISONE. Patient was hospitalized and became disabled. Patient recovered.
Myozyme Side Effects Report #6043379-X
Myozyme side effect was reported by a Physician from UNITED STATES on Jan 08, 2009. Male patient, weighting 12.13 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: candidiasis, catheter related infection, central line infection, clostridial infection, enterococcal infection, feeding disorder, fungaemia, hypercapnia, hyporeflexia. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with BUDESONIDE, XOPENEX, LANSOPRAZOLE, DIGOXIN, PROPANOLOL, AMIODARONE. Patient was hospitalized. Patient recovered.